Start with its own history
At 5.80×, IART is 88.7% below its 8-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NASDAQ · IARTMedical - DevicesUpdated Nov 2, 2026
Integra LifeSciences Holdings Corporation P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
5.80×
88.7% belowthe 8-observation annual average
Share price13.6764
÷Earnings per share2.36
Price and EPS in quote currency. Calculation details
Investors are paying 5.80 for every 1 of reported earnings per share.
P/E over time
2016 – 2025
Annual P/ESelected-period average 51.43×
3-year average50.06×1 positive annual observations
5-year average36.42×3 positive annual observations
10-year average51.43×8 positive annual observations
Peer median · TTM19.83×4 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2025 | N/M | N/M |
| Dec 31, 2024 | N/M | N/M |
| Dec 31, 2023 | 50.06× | +94.6% |
| Dec 31, 2022 | 25.72× | -23.2% |
| Dec 31, 2021 | 33.49× | -18.5% |
| Dec 31, 2020 | 41.09× | -58.4% |
| Dec 31, 2019 | 98.78× | +59.9% |
| Dec 31, 2018 | 61.78× | +7.1% |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2017 | 57.66× | +34.4% |
| Dec 31, 2016 | 42.90× | N/M |
| Dec 31, 2015 | N/M | N/M |
| Dec 31, 2014 | 52.14× | N/M |
| Dec 31, 2013 | N/M | N/M |
| Dec 31, 2012 | 26.33× | -11.2% |
| Dec 31, 2011 | 29.64× | +39.1% |
| Dec 31, 2010 | 21.31× | +1.7% |
| Dec 31, 2009 | 20.95× | -42.3% |
| Dec 31, 2008 | 36.30× | +5.6% |
| Dec 31, 2007 | 34.37× | -19.3% |
| Dec 31, 2006 | 42.59× | +48.9% |
| Dec 31, 2005 | 28.60× | -56.6% |
| Dec 31, 2004 | 65.95× | +111.7% |
| Dec 31, 2003 | 31.15× | +115.3% |
| Dec 31, 2002 | 14.47× | -40.7% |
| Dec 31, 2001 | 24.39× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How IART compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 IART This stockIntegra LifeSciences Holdings Corporation | 5.80× |
 SYKStryker Corporation | 32.32× |
 GMEDGlobus Medical, Inc. | 20.15× |
 ATECAlphatec Holdings, Inc. | N/M |
 SNNSmith & Nephew plc | 19.51× |
 OFIXOrthofix Medical Inc. | N/M |
 CNMDCONMED Corporation | 19.31× |
 TELATELA Bio, Inc. | N/M |
 AXGNAxoGen, Inc. | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does IART’s P/E tell you?
Compare like with like
The median of the 4 positive peer ratios above is 19.83×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take IART into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("IART", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 13.6764 ÷ EPS 2.36 = 5.80×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 2, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
IART P/E ratio: common questions
The essentials behind the numbers.
Integra LifeSciences Holdings Corporation's current P/E is 5.80× based on the quote data last updated Nov 2, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.